ArticleScientific reports2025
Analysis of the diagnostic accuracy of plasma sTNFr-2 concentrations in identifying sarcopenia in community-dwelling older women.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
While the potential of immunological biomarkers as an alternative to aid in the diagnosis, treatment, and monitoring of sarcopenia has been explored, there are still few studies evaluating their diagnostic accuracy. Specific biomarkers and diagnostic cutoff points remain unknown. Therefore, the objective of the present study was to verify the association between sarcopenia and a panel of inflammatory biomarkers and to investigate the diagnostic accuracy to propose cutoff points for this assessment. Accordance with EWGSOP2 guidelines, 71 community-dwelling older women participated in the study and were assessed for sarcopenia diagnosis. Dual-energy X-ray Absorptiometry (DXA), a Jamar dynamometer, and the Short Physical Performance Battery were used for diagnosis and classification of sarcopenia. A panel of biomarkers, including adiponectin, BDNF, IFN, IL-2, -4, -5, -6, -8, -10, leptin, resistin, TNF-α, and their soluble type 1 and 2 receptors, was measured using ELISA and flow cytometry. The associations between sarcopenia and a panel of biomarkers were verified by logistic regression analysis, and the cutoff points were determined using the ROC curve and Youden index. The sTNFr-2 was significantly associated with sarcopenia, showed good diagnostic accuracy and the optimal discriminatory cutoff point (AUC = 0.75) found was 2280 pg/ml in community-dwelling older women. These results provide valuable insights for the diagnosis, monitoring and understanding of the pathophysiology of sarcopenia in community-dwelling older women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.